Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

Future Opportunities With Interchangeable Biosimilars

August 15th 2023

A panel of experts discuss future opportunities with interchangeable biosimilars from payer and provider perspectives.

Addressing the Increased Amount of Interchangeable Biosimilars in the Market

August 15th 2023

Experts review best practices around plan design that payers and plan sponsors should address as more interchangeable biosimilars potentially enter the market.

Interchangeable Biosimilar Automatic Substitution

August 15th 2023

Jonathan Kay, MD, and Kimberly C. Chen, DO, MSHLM, discuss clinical and financial concerns related to automatic substitution at the pharmacy for an interchangeable biosimilar from a payer perspective.

Study: Ranibizumab Biosimilar Is the Most Cost-Effective Option for nAMD

August 15th 2023

By Justina Petrullo

Ranibizumab biosimilar was found to be the most cost-effective for neovascular age-related macular degeneration (nAMD), according to a recent Japanese study.

Contributor: The Promise of RA Biosimilars Could Be Realized, but Greater Adoption Rates Are Needed

August 14th 2023

By Robert Zutaut, RPh

Robert Zutaut, RPh, a clinical specialist from McKesson Provider Solutions, quantifies the major barriers to adoption for biosimilars used to treat rheumatoid arthritis (RA) and some major considerations for health systems looking to address them.

Oncological Biosimilars Shown to Be as Safe as Their Reference Products

August 13th 2023

By Gillian McGovern

Study finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.

Research Confirms Long-Term Stability of Adalimumab Biosimilar Candidate TUR01

August 12th 2023

By Deana Ferreri, PhD

A study on the stability of the adalimumab biosimilar candidate TUR01, a tumor necrosis factor-α inhibitor, found long-term stability of the drug substance and drug product were maintained under different temperatures.

The Top 5 Biosimilar Articles for the Week of August 7

August 11th 2023

By Justina Petrullo

Here are the top 5 biosimilar articles for the week of August 7, 2023.

Spanish Psoriasis Working Group Revises Guidelines for Biosimilars in Psoriasis

August 10th 2023

By Skylar Jeremias

The Spanish Psoriasis Working Group updated its position on the use of biosimilar medicines in patients with moderate to severe psoriasis, including its views on biosimilars as first-line treatment and nonmedical switching.

Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility

August 9th 2023

By Justina Petrullo

Streamlining biosimilar development would permit biosimilar development of more and a wider variety of biological drugs, fast-tracking biosimilar development without impacting patient safety or effectiveness, according to an opinion piece.